Key result
Warfarin therapy achieves therapeutic INR ~52% of the time, with frequent out-of-range readings of indeterminate cause.
Why the study?
The frequency and specific causes of overanticoagulation and underanticoagulation in patients receiving warfarin therapy managed in an anticoagulation clinic needed to be determined.
What are the frequency and causes of over- and underanticoagulation in patients receiving warfarin therapy?
Observational (n=1,020)
No
What are the frequency and causes of over- and underanticoagulation in patients receiving warfarin therapy?
Despite management in a dedicated anticoagulation clinic, out-of-range INRs are frequent and their specific causes often remain indeterminate.
Answers are grounded in this paper and cite their sources.
Out-of-range INRs remain common with mostly indeterminate causes despite clinic management; leaves open prospective studies to identify modifiable factors in warfarin therapy.
Study Objective. To determine the frequency and the specific causes of over‐and underanticoagulation in patients who receive warfarin therapy and are managed in an anticoagulation clinic. Design. Retrospective medical record review. Setting. University‐affiliated anticoagulation clinic. Subjects. One thousand twenty patients (mean age 60.2 yrs [range 17–84 yrs]) receiving warfarin therapy during a 1‐year index period. Measurements and Main Results. Of 12,897 international normalized ratios (INRs) evaluated, 6642 (51.5%) were within range and 8525 (66.1%) were within 0.2 INR units of range. Among 2881 out‐of‐range INRs below 2.0, the most common cause of underanticoagulation was indeterminate (856, 29.7%). Response to previous change in dosage (16.4%), noncompliance or dosing errors (16.3%), and initiation of therapy (15.6%) were other common causes of underanticoagulation. Changes in drugs, medical condition, dietary vitamin K intake, alcohol use, and activity level, in combination, accounted for only 15.1% of INRs below 2.0. Among 603 out‐of‐range INRs greater than 4.0, the most common cause of overanticoagulation was indeterminate (43.0%). Changes in medical condition (15.9%), response to a previous change in warfarin dosage (11.4%), and interactions with prescription drugs (7.3%) were other common causes of overanticoagulation. In combination, noncompliance or dosing errors, initiation of therapy, and change in dietary vitamin K intake accounted for only 15.4% of INR values above 4.0. Conclusion. Out‐of‐range INRs are encountered frequently during warfarin therapy as a result of changes in numerous factors. Despite extensive evaluation of potential causes of over‐ and underanticoagulation, a specific cause commonly cannot be determined.
No takes yet. Share an insight, caveat, or question.
Wittkowsky et al. (2004) conducted an observational in Anticoagulation therapy with warfarin (n=1,020). Warfarin therapy was evaluated on INRs within therapeutic range. Warfarin therapy yielded INRs within range 51.5% of the time, with indeterminate causes accounting for 29.7% of underanticoagulation (INR <2.0) and 43.0% of overanticoagulation (INR >4.0).
Synapse has enriched 10 related papers. Consider them for comparative context: